Please ensure Javascript is enabled for purposes of website accessibility

Here's Why AcelRx Pharmaceuticals Lost as Much as 18.4% Today

By Maxx Chatsko – Nov 9, 2018 at 1:43PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

After earning FDA marketing approval for a controversial new drug, the company is raising cash through a share offering.

What happened

Shares of AcelRx Pharmaceuticals (ACRX 2.14%) dropped over 18% today after the company announced a stock offering. The transaction will add up to 14.6 million shares to the market, an increase of 24% relative to the number of shares outstanding beforehand, and provide the company with gross proceeds of up to $46 million. As of 12:35 p.m. EST, the stock had settled to a 17.1% loss. 

It may be difficult to believe given today's massive decline in share price, but Wall Street appears to think the stock offering is a net positive for AcelRx Pharmaceuticals. That's because the decline in share price is less than the increase in shares outstanding. But why would that be the case?

A chart on a chalkboard showing steady gains and then a sudden decline.

Image source: Getty Images.

So what

The stock offering will pad the balance sheet with around $40 million in net proceeds once all transaction fees are paid. AcelRx Pharmaceuticals boasted $63.6 million in cash at the end of September, so this week's capital raise will go a long way to increasing the company's financial flexibility. It will need every penny. 

The drug developer recently scored a big regulatory approval for Dsuvia, a new opioid drug that received quite a bit of media attention. Some thought that the U.S. Food and Drug Administration, which has its hands full attempting to contain an ongoing opioid crisis that claimed over 30,000 lives in the United States last year, shouldn't be approving even more powerful opioids. But the regulatory body thought the company's plan for mitigating the risk of abuse was sufficient, and granted marketing approval.

AcelRx Pharmaceuticals will now begin the difficult and expensive transition from a development-stage to commercial-stage company. Thus, the recent stock offering and the capital it provides is being viewed by Wall Street as something that will increase the business's chances of success.

Now what

A market cap of just $250 million (including the new stock offering) implies that investors don't have much confidence in the market potential for Dsuvia. That's despite the fact that some analysts have projected peak annual sales for Dsuvia and Zalviso, the company's other approved pain medication, at a combined $1 billion or more.

Given the serious concerns over opioids, and the significant public pressure on the FDA and all levels of government to do everything they can to halt the worsening addiction crisis, investors can't discount the social and regulatory risks facing AcelRx Pharmaceuticals. Then again, the drug industry's political power in Washington can't be discounted, either.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AcelRx Pharmaceuticals Stock Quote
AcelRx Pharmaceuticals
ACRX
$0.22 (2.14%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.